NEJM releases ‘impressive’ peer-reviewed data for Pfizer COVID-19 vaccine candidate

by on

NEJM releases ‘impressive’ peer-reviewed data for Pfizer COVID-19 vaccine candidate
tjordan_drupal
Dec 10, 2020

Peer-reviewed data for Pfizer Inc.’s BNT162b2 mRNA COVID-19 vaccine candidate was published today by the New England Journal of Medicine, confirming its safety and efficacy.

The study’s authors concluded that a two-dose regimen of BNT162b2 conferred 95% protection against COVID-19 in individuals 16 years of age or older, with safety over a median of two months similar to that of other viral vaccines.

In an editorial accompanying the draft abstract, a team of NEJM editors called the data “impressive,” with a “remarkable level of safety and efficacy,” writing, “What appears to be a dramatic success for vaccination holds the promise of saving uncounted lives and giving us a pathway out of what has been a global disaster.”

Headline

NEJM releases ‘impressive’ peer-reviewed data for Pfizer COVID-19 vaccine candidate
tjordan_drupal
Dec 10, 2020

Peer-reviewed data for Pfizer Inc.’s BNT162b2 mRNA COVID-19 vaccine candidate was published today by the New England Journal of Medicine, confirming its safety and efficacy.

The study’s authors concluded that a two-dose regimen of BNT162b2 conferred 95% protection against COVID-19 in individuals 16 years of age or older, with safety over a median of two months similar to that of other viral vaccines.

In an editorial accompanying the draft abstract, a team of NEJM editors called the data “impressive,” with a “remarkable level of safety and efficacy,” writing, “What appears to be a dramatic success for vaccination holds the promise of saving uncounted lives and giving us a pathway out of what has been a global disaster.”

COVID-19: Vaccines and Therapeutics
Novel Coronavirus (SARS-CoV-2/COVID-19)

Headline

VA:F [1.9.7_1111]
Rating: 0.0/10 (0 votes cast)
VA:F [1.9.7_1111]
Rating: 0 (from 0 votes)

Leave a Comment

Previous post:

Next post: